[go: up one dir, main page]

CL2019003172A1 - Brimonidina destinada al uso y diseño de ensayos clínicos para la atrofia geográfica debido a una degeneración macular asociada a la edad. - Google Patents

Brimonidina destinada al uso y diseño de ensayos clínicos para la atrofia geográfica debido a una degeneración macular asociada a la edad.

Info

Publication number
CL2019003172A1
CL2019003172A1 CL2019003172A CL2019003172A CL2019003172A1 CL 2019003172 A1 CL2019003172 A1 CL 2019003172A1 CL 2019003172 A CL2019003172 A CL 2019003172A CL 2019003172 A CL2019003172 A CL 2019003172A CL 2019003172 A1 CL2019003172 A1 CL 2019003172A1
Authority
CL
Chile
Prior art keywords
brimonidine
age
design
intended
clinical trials
Prior art date
Application number
CL2019003172A
Other languages
English (en)
Inventor
Kevin Kerr
Francisco Lopez
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2019003172A1 publication Critical patent/CL2019003172A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

MÉTODOS PARA TRATAR O DESACELERAR EL CRECIMIENTO DE UNA LESIÓN ASOCIADA A LA ATROFIA GEOGRÁFICA Y MÉTODOS PARA EVALUAR UN MEDICAMENTO (BRIMONIDINA) O AGENTE PARA SU USO EN EL TRATAMIENTO, LA REDUCCIÓN DE LA EVOLUCIÓN O LA DESACELERACIÓN DEL CRECIMIENTO DE UNA LESIÓN ASOCIADA A LA ATROFIA GEOGRÁFICA.
CL2019003172A 2017-05-05 2019-11-05 Brimonidina destinada al uso y diseño de ensayos clínicos para la atrofia geográfica debido a una degeneración macular asociada a la edad. CL2019003172A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762502375P 2017-05-05 2017-05-05

Publications (1)

Publication Number Publication Date
CL2019003172A1 true CL2019003172A1 (es) 2020-04-13

Family

ID=62555156

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003172A CL2019003172A1 (es) 2017-05-05 2019-11-05 Brimonidina destinada al uso y diseño de ensayos clínicos para la atrofia geográfica debido a una degeneración macular asociada a la edad.

Country Status (14)

Country Link
US (2) US20180318302A1 (es)
EP (1) EP3618832A1 (es)
JP (1) JP2020518626A (es)
KR (1) KR20190142399A (es)
CN (1) CN110769829A (es)
AU (1) AU2018261171A1 (es)
BR (1) BR112019023223A2 (es)
CA (1) CA3062455A1 (es)
CL (1) CL2019003172A1 (es)
MX (1) MX2019013192A (es)
PH (1) PH12019502483A1 (es)
RU (1) RU2019136781A (es)
WO (1) WO2018204759A1 (es)
ZA (1) ZA201907329B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115485717A (zh) * 2020-03-23 2022-12-16 基因泰克公司 使用分割和特征评估预测地图状萎缩进展
CN113035298B (zh) * 2021-04-02 2023-06-20 南京信息工程大学 递归生成大阶数行限制覆盖阵列的药物临床试验设计方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
HK1218850A1 (zh) * 2013-02-15 2017-03-17 Allergan, Inc. 持续药物递送植入物

Also Published As

Publication number Publication date
AU2018261171A1 (en) 2019-12-05
BR112019023223A2 (pt) 2020-05-26
CN110769829A (zh) 2020-02-07
WO2018204759A1 (en) 2018-11-08
MX2019013192A (es) 2020-01-13
EP3618832A1 (en) 2020-03-11
RU2019136781A (ru) 2021-06-07
US20210213017A1 (en) 2021-07-15
CA3062455A1 (en) 2018-11-08
KR20190142399A (ko) 2019-12-26
ZA201907329B (en) 2021-05-26
US20180318302A1 (en) 2018-11-08
PH12019502483A1 (en) 2020-07-20
JP2020518626A (ja) 2020-06-25

Similar Documents

Publication Publication Date Title
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
MX2024000348A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
BR112018012182A2 (pt) dispositivo para tratamento fotodinâmico
MX381718B (es) Agentes biologicos y su uso en plantas.
CL2016002372A1 (es) Cenicriviroc para el tratamiento de la fibrosis.
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
CL2015002835A1 (es) Nuevos derivados de piridina
NI201500118A (es) Imidazopiridazinas sustituidas
CL2018001913A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CO2017005968A2 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2018001804A1 (es) Uso de la carrimicina en la infección por micobacterium tuberculosis resistente
CL2018001911A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CO2018008449A2 (es) Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2018001104A1 (es) Composición para el cuidado de la piel y procedimiento asociado.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2019001225A (es) Compuesto aromatico heterociclico nitrogenoso, metodo de preparacion del mismo, composicion farmaceutico del mismo y aplicacion del mismo.
CL2019003172A1 (es) Brimonidina destinada al uso y diseño de ensayos clínicos para la atrofia geográfica debido a una degeneración macular asociada a la edad.
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
BR112016016842A2 (pt) Composição compreendendo um herbicida seletivo e um extrato de algas, uso de um extrato de algas para desintoxicar plantas submetidas ao tratamento com um herbicida seletivo
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
UA115417U (xx) Спосіб профілактики та лікування гіпоксичних змін при карбоперитонеумі